Transforming medical devices for improved patient outcomes

Micell Technologies Announces Expanded Patent Estate – Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Durham, NC – March 20, 2018 — Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio. With the granting of 24 patents in 2017, including eight that issued in the fourth quarter, Micell’s extensive intellectual property portfolio comprises 186 patents (166 issued and 20 allowed) protecting the company’s novel drug-eluting stent, its enabling technologies, and future biomedical and other applications.

Micell’s technology platform uses unique surface modification and polymer science to allow for precisely and consistently controlled drug elution. This technology made possible the successful development of Micell’s drug-eluting stent, the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent). The device is designed to optimize clinical performance and healing compared to other currently available drug-eluting coronary stents.

“Patents issued throughout the past year represent external validation of Micell’s innovative approach to controlled drug delivery. Beyond MiStent, this platform technology potentially allows for diverse and broadly based biomedical applications that could address unmet clinical needs.  To date, there are more than 8,410 claims — issued, allowed and pending — associated with Micell’s patents, and additional patent applications currently are pending,” said Arthur J. Benvenuto, Micell’s Chairman and CEO.

Editor’s Note:  For detailed information related to Micell’s intellectual property portfolio, please contact Micell Technologies.

About Micell’s Core Technology

Micell’s supercritical fluid technology is used in applying a polymer and drug coating to a substrate (e.g., a stent platform) while preserving the crystalline integrity of the drug during the coating process. Fusing the polymer — applied using supercritical fluid technology — and the dry crystalline form of the drug creates a smooth, uniform, well-adhered drug-delivery formulation on the substrate and could be an enabling core technology for broad medical device and biopharmaceutical applications. Early aspects of this solvent-free coating technology were developed in conjunction with Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory managed by Battelle Memorial Institute.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements that can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements include words such as “anticipates,” “estimates,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance in connection with the results of a post-marketing clinical program and the commercialization and sale of MiStent in Europe and other markets. We caution readers that the forward-looking statements contained in this press release are predictions based on our current analysis of, and expectations about, future events and speak only as of the date of this press release. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to, the following: the results of any further clinical trials and studies; our ability to obtain regulatory approval of the MiStent in other jurisdictions; the successful development and commercialization of MiStent in Europe and other markets; the ability of MiStent to effectively and successfully compete with current commercially available drug-eluting stent technologies in Europe and other markets; and our ability to maintain and protect our proprietary stent coating technology. Actual results, performance or achievements could differ materially and adversely from those expressed or implied by any forward-looking statement contained in this press release.

Micell, the Micell logo, and MiStent are among the trademarks of Micell Technologies, Inc.

Contact for Micell Technologies

Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104